secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001214659-24-004200
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro files amended Series B preferred stock designation and eliminates Series A
--------------------------------------------------------------------------------

- Filed amended and restated certificate of designations for Series B preferred stock on March 1, 2024.
- Amendment corrects references from Series A to Series B and clarifies voting rights per Nasdaq rules.
- Filed certificate of elimination to remove Series A convertible preferred stock from charter, effective March 1, 2024.
- No changes to preferences and rights of Series B beyond the correction and clarification.
- All actions are procedural with no financial or operational impact disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924004200/0001214659-24-004200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924004200/g362408k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-004200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer